Interestingly, pharmacological inhibition of the DX2–ARF interaction delays tumor growth, suggesting that restoration of ARF in lung cancer can be achieved by manipulation of single pathways, notwithstanding the several factors aiming at its destruction (14). This evidence concerns the gene CDKN2A and neoplasm.